MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis (original) (raw)

Abstract

MK-591 acutely restores glomerular size selectivity and reduces disease (ESRD) [1]. Despite an increasing understanding proteinuria in human glomerulonephritis. of the pathogenetic mechanisms that mediate immune Background. Leukotrienes are 5-lipoxygenated (5-LO) meglomerular damage, the treatment of glomerulonephritis tabolites of arachidonic acid that mediate some of the glomeruis still unsatisfactory. The treatment of glomerulonephrilar hemodynamic and structural changes in experimental and tis with nonselective immunosuppression, mostly with human glomerulonephritis. Methods. We conducted an open-label, pilot study of the cytotoxic agents, has yielded encouraging results in some short-term effects of leukotriene biosynthesis inhibition using forms of glomerulonephritis such as lupus nephritis [2], an orally active 5-LO activating protein (FLAP) antagonist but is associated with significant morbidity [2-4]. In the (MK-591) on glomerular function in patients with glomerulonelast 10 to 15 years, there have been significant advances phritis. Eleven adult patients (seven women, median age 38 in the understanding of the pathogenesis of glomerular years) with glomerulonephritis (5 lupus nephritis, 2 IgA nephropathy, 1 membranoproliferative, 1 membranous, 1 C1qinflammation, mostly gathered from experimental moddeficiency, and 1 idiopathic crescentic) and moderate renal els [5-8]. In animals with experimentally induced glomerinsufficiency [glomerular filtration rate (GFR) 62 Ϯ 9 ml/min/ ulonephritis, an initial deposition of immune complexes 1.73 m 2 ] were given MK-591 at a dose of 100 mg orally twice in the glomerulus is followed by recruitment and activaa day for four days. Results. MK-591 reduced proteinuria (albumin and IgG ex-tion of blood polymorphonuclear leukocytes (PMNs), cretion rates) from 3233 Ϯ 1074 to 1702 Ϯ 555 g/min and followed by influx of lymphocytes, macrophages, and from 196 Ϯ 78 to 148 Ϯ 55 g/min for albumin and IgG, platelets. These in turn generate a cascade of immune respectively (P Ͻ 0.05 for both). This was not accompanied mediators-interleukins, prostanoids, complement, oxyby a reduction in systemic arterial pressure, GFR, or renal gen radicals, etc.-that promotes further cellular events plasma flow. By analysis of the fractional clearance of polydisperse dextrans, baseline proteinuria resulted from a loss of size Key words: leukotrienes, glomerular inflammation, dextran sieving, transglomerular protein trafficking. filtration rate (GFR). Furthermore, an acute blockade of LTD 4 in models of nephrotoxic serum nephritis [10],

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (20)

  1. Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor a distinct pattern of glomerular dysfunction. Kidney Int 51:826- 833, 1997
  2. G, Rubin P, Drazen JM: The effects of a 5-lipoxygenase inhibitor 30. Deen WM, Bridges CR, Brenner BM, Myers BD: Heteroporous on asthma induced by cold, dry air. N Engl J Med 323:1740-1744, model of glomerular size selectivity: Application to normal and 1990 nephrotic humans. Am J Physiol 249:F374-F389, 1985
  3. Knapp HR: Reduced allergen-induced nasal congestion and leuko- 31.
  4. Guasch A, Myers BD: Determinants of glomerular hypofiltration triene synthesis with an orally active 5-lipoxygenase inhibitor. N in nephrotic patients with minimal change nephropathy. J Am Soc Engl J Med 323:1745-1748, 1990 Nephrol 4:1571-1581, 1994
  5. Uematsu T, Kanamaru M, Kosuge K, Hara K, Uchiyama N, 32. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek
  6. Takenaga N, Tanaka W, Friedman BS, Nakashima M: Pharmaco- JW, Striker G: The effects of dietary protein restriction and blood- kinetic and pharmacodynamic analysis of a novel leukotriene bio- pressure control on the progression of chronic renal disease: Modi- synthesis inhibitor, MK-0591, in healthy volunteers. Br J Clin Phar- fication of Diet in Renal Disease Study Group. N Engl J Med macol 40:59-66, 1995 330:877-884, 1994
  7. Hillingso J, Kjeldsen J, Laursen LS, Lauritsen K, Von Spreck- 33.
  8. Myers BD, Nelson RG, Tan M, Beck GJ, Bennett PH, Knowler elsen S, Depre M, Friedman BS, Malmstrom K, Shingo S, Buk- WC, Blouch K, Mitch WE: Progression of overt nephropathy in have K, Rask-Madsen J: Blockade of leukotriene production by non-insulin-dependent diabetes. Kidney Int 47:1781-1789, 1995
  9. a single oral dose of MK-0591 in active ulcerative colitis. Clin 34. Scandling JD, Black VM, Deen WM, Myers BD: Glomerular Pharmacol Ther 57:335-341, 1995 permselectivity in healthy and nephrotic humans. Adv Nephrol
  10. Depre M, Friedman B, Van Hecken A, de Lepeleire I, Tanaka Necker Hosp 21:159-176, 1992
  11. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of W, Dallob A, Shingo S, Porras A, Lin C, de Schepper PJ: Phar- altered glomerular permeability to macromolecules? Kidney Int macokinetics and pharmacodynamics of multiple oral doses of MK- 38:384-394, 1990
  12. 0591, a 5-lipoxygenase-activating protein inhibitor. Clin Pharmacol 36. Eddy AA, Giachelli CM: Renal expression of genes that promote Ther 56:22-30, 1994 interstitial inflammation and fibrosis in rats with protein-overload
  13. Deleted in proof. proteinuria. Kidney Int 47:1546-1557, 1995
  14. Guasch A, Hashimoto H, Sibley RK, Deen WM, Myers BD: 37. Zoja C, Morigi M, Figliuzzi M, Bruzzi I, Oldroyd S, Benigni Glomerular dysfunction in nephrotic humans with minimal changes A, Ronco P, Remuzzi G: Proximal tubular cell synthesis and secre- or focal glomerulosclerosis. Am J Physiol 260:F728-F737, 1991 tion of endothelin-1 on challenge with albumin and other proteins.
  15. Guasch A, Sibley RK, Huie P, Myers BD: Extent and course of Am J Kidney Dis 26:934-941, 1995
  16. glomerular injury in human membranous glomerulopathy. Am J 38. Benigni A, Remuzzi G: Glomerular protein trafficking and pro- Physiol 263:F1034-F1043, 1992 gression of renal disease to terminal uremia. Semin Nephrol 16:
  17. Guasch A, Cua M, Mitch WE: Extent and the course of glomeru- 151-159, 1996
  18. lar injury in patients with sickle cell anemia. Kidney Int 49:786- 39.
  19. Rossing P, Hommel E, Smidt UM, Parving HH: Reduction in 791, 1996 albuminuria predicts diminished progression in diabetic nephropa- thy. Kidney Int 45(Suppl 45):S145-S149, 1994
  20. Guasch A, Cua M, You W, Mitch WE: Sickle cell anemia causes